Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR].
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms SuMR
- 05 Mar 2010 Results were presented at ASCO 2010 Genitourinary Cancers Symposium for an analysis of the effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated clear cell renal cancer.
- 05 Dec 2009 New trial record